As a result of the U.S. tax law passed in December, AbbVie plans to make investments of roughly $2.5 billion over the next five years in capital projects in the United States, as well as a one-time contribution of $350 million to select charitable organizations in 2018 and enhancements to nonexecutive employee compensation and other benefits.
The company reported its fourth-quarter segments as follows:
- Humira revenues increased 14.0% to $4.89 billion.
- Imbruvica revenues increased 38.7% to $708 million.
- HCV revenues increased 63.4% to $510 million.
- Lupron revenues increased 2.2% to $224 million.
- Creon revenues increased 10.6% to $235 million.
- Synagis revenues increased 4.4% to $282 million.
- Synthroid had revenues of $205 million.
- AndroGel revenues decreased 19.6% to $140 million.
- Kaletra revenues decreased 14.3% to $113 million.
- Sevoflurane revenues decreased 1.5% to $99 million.
- Duodopa revenues increased 27.6% to $100 million.
Looking ahead to 2018, AbbVie is raising its previously announced EPS guidance range for the full year to $7.33 to $7.43 from $6.37 to $6.57 to reflect the impact of U.S. tax reform and stronger operating performance. Consensus estimates call for $6.59 in EPS and $31.04 billion in revenue for the 2018 full year.
Richard A. Gonzalez, AbbVie’s board chair and chief executive, commented:
2017 reflects another year of top-tier performance, demonstrating the strong momentum in our business. Our guidance for 2018 underscores our confidence in our ability to continue to deliver industry-leading performance. This is an exciting time for AbbVie — we are poised to launch a number of differentiated products over the next 12 to 18 months that will fuel significant growth in the coming years. We remain committed to delivering on our long-term strategic vision for AbbVie.
Shares of AbbVie closed Thursday at $108.30, with a consensus analyst price target of $103.00 and a 52-week trading range of $59.27 to $108.37. Following the announcement, the stock was up 2.5% at $111.00 in early trading indications Friday.
Are You Still Paying With a Debit Card?
The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.
Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!
Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!
Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.